Healwell AI

The firm has an exclusive strategic partnership with WELL Health Technologies, Canada's largest digital-health ecosystem, granting it access to more than 40,000 healthcare providers and 5 million yearly patient visits. This embedded channel allows Healwell to deploy its disease-screening tools directly inside existing clinical workflows and to train its algorithms on permissioned, real-world Canadian patient data.

Healwell pursues a dual-track M&A strategy. One track targets other AI companies focused on early disease detection; the other acquires mature healthcare-software operators with strong financial fundamentals, which Healwell then aims to enhance by layering on its own AI technology. The firm describes the combined entity as a capital allocator scaling rapidly through acquisition.

Its wholly owned subsidiary Khure Health runs rare- and specialty-disease screening programs with 6 of the top 10 pharmaceutical companies, generating real-world evidence studies. The firm also operates BioPharma Services, a Toronto-based CRO that conducts Phase 1 and Phase 2a clinical trials for pharmaceutical and biotech clients.

No. Healwell operates as a publicly listed operating company that acquires and integrates healthcare technology businesses. It does not market a fund vehicle for external limited partners; its balance sheet is the investment vehicle.

Healwell holds a mix of wholly owned entities (Khure Health, Intrahealth, BioPharma Services) and majority stakes (Pentavere Research Group). It also carries strategic investments in companies such as doctorly, xAI, Mutuo Health Solutions, Abstractive Health, and Orion Health. The precise ownership percentages on the minority investments are not publicly disclosed.